脓毒症微循环功能障碍的生物标志物:一项前瞻性观察性预试验
该前瞻性观察性病例对照研究在丹佛健康医疗中心纳入44例脓毒症或脓毒性休克成人患者和24例择期骨科手术健康对照,评估舌下显微(SLM)、尿糖胺聚糖(GAG)DMMB比色法和LC-MS/MS定量GAGs作为微血管功能障碍生物标志物。结果显示LC-MS/MS检测硫酸乙酰肝素(HS)在脓毒症组显著高于对照组(AUC 0.85;95%CI 0.76-0.95),诊断性能高于SLM(De Backer密度AUC 0.71)和DMMB GAGs(AUC 0.62);LC-MS/MS与HILIC-MS的HS水平强相关(R²=0.97,p<0.001)。DMMB GAGs与HS亚型(p=0.05)和SLM密度(p=0.03)相关,但与院内死亡率或急性肾损伤无显著关联。作者认为LC-MS/MS定量HS在评估的模态中鉴别脓毒症能力最强,SLM诊断效用中等且与GAG水平相关,但床旁应用可能受图像采集和分析限制。
要点
- 在44例脓毒症或脓毒性休克成人患者与24例健康对照中,LC-MS/MS定量尿HS的AUC为0.85(95%CI 0.76-0.95),高于SLM的De Backer密度AUC 0.71和DMMB GAGs的AUC 0.62。
- LC-MS/MS与HILIC-MS测定的HS水平强相关(R²=0.97,p<0.001),支持LC-MS/MS作为可扩展的快速检测平台。
- DMMB GAGs与HS亚型相关(p=0.05),与SLM密度相关(p=0.03),提示舌下显微与GAG水平具有生物学相关性。
- LC-MS/MS HS、SLM参数和DMMB GAGs均与院内死亡率或急性肾损伤无显著关联。
- 作者认为SLM床旁应用可能受图像采集和分析挑战限制,而LC-MS/MS在脓毒症试验和临床 care 中具有生物标志物驱动富集的潜力。
适用人群与场景
- 成人脓毒症或脓毒性休克患者(44例),以及接受择期骨科手术的健康对照(24例)。
- 排除标准包括妊娠和被监禁者。
- 研究场所为丹佛健康医疗中心(Denver Health Medical Center),一家安全网医院。
研究设计与关键结果
- 研究类型为前瞻性观察性病例对照研究,纳入44例脓毒症或脓毒性休克成人患者和24例健康对照。
- 主要终点:LC-MS/MS测定的尿HS在脓毒症组显著高于对照组(AUC 0.85;95%CI 0.76-0.95),诊断性能高于SLM的De Backer密度(AUC 0.71)和DMMB GAGs(AUC 0.62)。
- LC-MS/MS与HILIC-MS测定的HS水平强相关(R²=0.97,p<0.001)。
- DMMB GAGs与HS亚型相关(p=0.05),与SLM密度相关(p=0.03)。
- 未观察到与院内死亡率或急性肾损伤的显著关联。
证据类型、等级与局限
- 证据类型:前瞻性观察性病例对照研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为LC-MS/MS定量HS在评估的模态中鉴别脓毒症能力最强,与已建立的质谱方法强相关,有望作为可扩展、快速且机制信息丰富的平台用于未来脓毒症试验和临床 care 中的生物标志物驱动富集。
- 作者指出SLM诊断效用中等且与GAG水平显著相关,但其床旁应用可能受图像采集和分析挑战限制。
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
CONTEXT: To evaluate and compare sublingual microscopy (SLM) to urinary glycosaminoglycan (GAG) assays, dimethylmethylene blue (DMMB) assay, and liquid chromatography tandem mass spectrometry (LC-MS/MS) quantification of GAGs as biomarkers of microvascular dysfunction in patients with sepsis and septic shock.
HYPOTHESIS: Indicators of microvascular dysfunction and markers of endothelial glycocalyx (eGC) degradation would be associated with sepsis.
METHODS AND MODELS: Prospective, observational case-control study.
SETTING: Denver Health Medical Center, a safety-net hospital in Denver, CO.
SUBJECTS: Forty-four adult patients with sepsis or septic shock and 24 healthy control patients undergoing elective orthopedic procedures. Exclusion criteria included pregnancy and incarceration.
RESULTS: Sublingual microvascular parameters (De Backer Density, proportion of perfused vessels) were measured using darkfield sidestream microscopy, and urinary GAGs were measured via DMMB colorimetric assay and LC-MS/MS targeting heparan sulfate (HS), dermatan sulfate, and keratan sulfate. Validation of HS quantification was performed on a subset using hydrophilic interaction liquid chromatography-mass spectrometry (HILIC-MS). LC-MS/MS HS was significantly higher in sepsis vs. controls (Area under the curve 0.85; 95% CI, 0.76-0.95), demonstrating higher diagnostic performance than SLM (De Backer Density AUC 0.71) and DMMB GAGs (AUC 0.62). LC-MS/MS and HILIC-MS HS levels were strongly correlated (R² = 0.97, p < 0.001). DMMB GAGs were associated with HS subtypes (p = 0.05) and SLM density (p = 0.03). No significant associations with in-hospital mortality or acute kidney injury were observed.
INTERPRETATION AND CONCLUSIONS: Among the evaluated modalities, LC-MS/MS quantification of HS showed the greatest discriminative ability for identifying sepsis and correlated strongly with established mass spectrometric methods. SLM exhibited moderate diagnostic utility and significant associations with GAG levels, reinforcing its biologic relevance. However, its bedside application may be limited by challenges in image acquisition and analysis. The concordance across SLM, DMMB, and LC-MS/MS supports eGC degradation as a key feature of sepsis pathophysiology. These findings highlight the promise of LC-MS/MS as a scalable, rapid, and mechanistically informed platform for biomarker-driven enrichment in future sepsis trials and clinical care.
参考来源
- Longino A, Martin K, Bourland S, et al. Biomarkers of Microcirculatory Dysfunction in Sepsis: A Pilot Prospective Observational Study. Crit Care Explor. 2025. PMID: 41065504. doi:10.1097/CCE.0000000000001324
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。